Lupus Innovation Award (LIA)
The Lupus Innovation Award ($300,000 for 2 years) provides early-stage support for highly innovative approaches to major challenges in lupus research If you are a researcher and would like to learn more about our funded research please click here.
Lupus Mechanisms and Targets Award (LMTA)
The Lupus Mechanisms and Targets Award ($600,000 for 3 years) supports research focused on the identification and/or investigation of molecular pathways or targets that could lead to new or improved therapies for people with lupus. If you are a researcher and would like to learn more about our funded research please click here.
Pharmaceutical and Biotech Support of the Lupus Research Alliance – 2019
Pharmaceutical and Biotech Support of the Lupus Research Alliance – 2019 The Lupus Research Alliance’s vision is a world free of lupus – by finding ways to prevent, treat and one day cure this disease. We work diligently to forge appropriate relationships with members of the pharmaceutical and biotech industries that share our vision and […]
Pharmaceutical and Biotech Support of the Lupus Research Alliance – 2020
Pharmaceutical and Biotech Support of the Lupus Research Alliance – 2020 The Lupus Research Alliance’s vision is a world free of lupus – by finding ways to prevent, treat and one day cure this disease. We work diligently to forge appropriate relationships with members of the pharmaceutical and biotech industries that share our vision and […]
Good News on Lupus Nephritis Discoveries from ACR Convergence 2020
November 19, 2020 The LRA is proud to share the extraordinary work presented at ACR Convergence 2020 by research members of the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE). AMP is a public-private partnership between the National Institutes of Health (NIH), eight biopharmaceutical companies, the LRA and several […]
Lupus Nephritis: A Major Focus at the Lupus Research Alliance
Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […]
LRA-BMS Accelerator Awards (BMS)
The LRA-BMS Accelerator Award ($300,000 for 2 years) is a collaborative project with sponsoring partner Bristol Myers Squibb supporting research on understanding human lupus heterogeneity and identifying novel biomarkers. If you are a researcher and would like to learn more about our funded research please click here.
LRA Highlights Full Continuum of Lupus Research at ACR Convergence 2020
30+ presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from three clinical studies conducted in part by LRA-affiliate Lupus Therapeutics (LT) through its trials network 10 lupus presentations by the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE) NEW YORK, NY, […]
LuCIN FAQ
Frequently Asked Questions About the Lupus Clinical Investigators Network (LuCIN) Clinical Research Program About LuCIN 1. What is LuCIN? Lupus Clinical Investigators Network (LuCIN) is a Lupus clinical trials network, made up of 57 of the most prestigious academic research medical centers throughout North America. Founded and sponsored by the Lupus Research Alliance, LuCIN brings […]
Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)
First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month NEW YORK, NY. January 22, 2021. The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals’ LupkynisTM (voclosporin) as the first oral treatment developed specifically for […]